drugset / Trial / NCT00489918

Dose Ranging Study - Macroflux Parathyroid Hormone (PTH) in Postmenopausal Women With Osteoporosis

NCT00489918

Phase 2 Completed 165 enrolled Zosano Pharma Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Multi-center study to determine effects of various doses of Macroflux Parathryroid Hormone (PTH) in women with osteoporosis

Timeline

Start
2007-06
Primary completion
2008-04
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Teriparatide Protein / enzyme biologic 20 ug Other
Comparator Teriparatide Protein / enzyme biologic 20 ug Subcutaneous
Comparator Teriparatide Protein / enzyme biologic 30 ug Other
Comparator Teriparatide Protein / enzyme biologic 40 ug Other

Indications